Phaseline

Targets › PDGFRB

PDGFRB (Platelet-derived growth factor receptor beta): drug programs, companies and trials

33 programs from 28 companies in 194 trials: 119 Phase 2, 47 Phase 1, 24 Phase 3, 4 Phase 4; Oncology, Respiratory, Other; next expected readout Dec 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth…. (UniProt, P09619)

Open in Phaseline: the race on PDGFRB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chia Tai Tianqing Pharmaceutical GroupCatequentinib
Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor
KDR, FLT4, KIT, PDGFRBPhase 4Medullary Thyroid Cancer; Advanced Hepatocellular Carcinoma (HCC); Metastatic Colorectal Cancer; Hepatocellular Carcinoma …Dec 2026
Gossamer Bio USASeralutinib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor
KIT, PDGFRB, PDGFRA, CSF1RPhase 3Pulmonary Arterial HypertensionDec 2026
Daiichi SankyoQuizartinib
Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor
CSF1R, FLT3, KIT, PDGFRB, PDGFRAPhase 3Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult …May 2027
Jiangsu HengRui MedicineFamitinib
Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
KIT, FLT1, FLT3, PDGFRB, PDGFRAPhase 3Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm …May 2027
Advenchen LaboratoriesCatequentinib (AL3818)
Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor
KDR, FLT4, KIT, PDGFRBPhase 3Alveolar Soft Part SarcomaDec 2027
AB ScienceMasitinib
Fibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor
FGFR3, KIT, PDGFRB, PDGFRAPhase 3Amyotrophic Lateral SclerosisDec 2027
Alliance for Clinical Trials in OncologyTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 3Clear Cell Renal Cell CarcinomaNov 2037
RocheSorafenib
Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
RAF1, PDGFRB, KIT, FLT3, BRAFPhase 3Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma …–
M.D. Anderson Cancer CenterSunitinib Malate
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Renal Cell Carcinoma; Malignant Neoplasms of Urinary Tract; Prostate CancerDec 2026
National Cancer Institute (NCI)Sunitinib Malate
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Advanced Lymphoma; Metastatic Pancreatic Neuroendocrine TumorDec 2026
Avalyn PharmaNintedanib (AP02)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer …Dec 2026
Sun Yat-sen UniversityAnlotinib Hydrochloride
Multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, FLT1, KIT, and RET
VEGFR, PDGFRA, PDGFRB, FLT1, KITPhase 2GlioblastomaDec 2026
Canadian Cancer Trials GroupSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Advanced Rare TumoursDec 2026
University of MiamiSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Gastrointestinal Stromal TumorsDec 2026
National Cancer Institute (NCI)Imatinib Mesylate
Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
ABL1, PDGFRB, KIT, BCRPhase 2Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia; Inherited Bone Marrow Failure SyndromeMar 2027
National Cancer Institute (NCI)Sorafenib Tosylate
Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
RAF1, PDGFRB, KIT, FLT3, BRAFPhase 2Gastrointestinal Stromal Tumor; Acute Myeloid Leukemia; Advanced Malignant Solid NeoplasmMar 2027
Sarcoma Alliance for Research through CollaborationSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Gastrointestinal Stromal TumorsJun 2027
MannkindNintedanib (MNKD-201)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary FibrosisDec 2027
American Society of Clinical OncologySunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Lymphoma, Non-HodgkinDec 2027
Bai-Rong XiaSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2Ovary CancerDec 2027
Memorial Sloan Kettering Cancer CenterSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 2OsteosarcomaMar 2028
M.D. Anderson Cancer CenterTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 2Renal Cell CarcinomaNov 2028
NovartisMidostaurin
Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor
FLT3, KIT, PDGFRB, PDGFRA, PRKD3Phase 2FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid LeukemiaMay 2029
Taiho PharmaceuticalImatinib
Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
ABL1, PDGFRB, KIT, BCRPhase 1Gastrointestinal Stromal Tumors; Hematological Neoplasms; Tyrosine Kinase Inhibitors; Leukemia, Acute Lymphoblastic …Dec 2026
University of FloridaTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 1Bile Duct CancerDec 2026
AstraZenecacediranib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
KIT, PDGFRB, PDGFRA, FLT1, FLT4Phase 1Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer …Dec 2026
Betta PharmaceuticalsX-82
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 1DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib …Jan 2027
Etnova TherapeuticsETN101
Multiple tyrosine kinase inhibitor targeting FLT3, KIT, VEGFR2, and PDGFRB
FLT3, KIT, VEGFR2, PDGFRBPhase 1Hepatocellular CarcinomaMar 2027
State University of New York at BuffaloSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1Carcinoma, Renal CellJul 2027
University of Colorado, DenverSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1OsteosarcomaAug 2027
Rabin Medical CenterSunitinib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
CSF1R, KIT, FLT3, PDGFRB, PDGFRAPhase 1Solid Tumors Refractory to Standard TherapyJan 2028
National Cancer Institute (NCI)Tivozanib (AV-951)
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 1CholangiocarcinomaDec 2028
Sun Yat-sen UniversityKDR2-2 suspension eyedrop
VEGFR2 inhibitor with moderate PDGFRβ inhibition
KDR, PDGFRBPhase 1Neovascular Glaucoma–

Conditions

Acute Myeloid Leukemia (10) Hepatocellular Carcinoma (6) Gastrointestinal Stromal Tumors (5) Cervical Cancer (4) Breast Cancer (4) Soft Tissue Sarcoma (3) Non-Small Cell Lung Cancer (3) Non-small Cell Lung Cancer (3) Non Small Cell Lung Cancer (2) Alveolar Soft Part Sarcoma (2) Locally Advanced Thyroid Gland Carcinoma (2) Unresectable Hepatocellular Carcinoma (2)

Modalities

small molecule (24), mixed (6), antibody (2), other (1)

Companies

National Cancer Institute (NCI) (4) Sun Yat-sen University (2) M.D. Anderson Cancer Center (2) Canadian Cancer Trials Group (1) Chia Tai Tianqing Pharmaceutical Group (1) Novartis (1) Avalyn Pharma (1) Alliance for Clinical Trials in Oncology (1) Gossamer Bio USA (1) University of Florida (1) Daiichi Sankyo (1) Mannkind (1) Etnova Therapeutics (1) Memorial Sloan Kettering Cancer Center (1) Advenchen Laboratories (1) Taiho Pharmaceutical (1) University of Colorado, Denver (1) AstraZeneca (1) Sarcoma Alliance for Research through Collaboration (1) Jiangsu HengRui Medicine (1)

Related targets

KIT (29) PDGFRA (21) FLT3 (17) CSF1R (13) KDR (10) FLT4 (10) FLT1 (10) RAF1 (2) BRAF (2) ABL1 (2) BCR (2) PRKD3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.